These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38657050)

  • 1. The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.
    Sherman DJ; Liu L; Mamrosh JL; Xie J; Ferbas J; Lomenick B; Ladinsky MS; Verma R; Rulifson IC; Deshaies RJ
    Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2318619121. PubMed ID: 38657050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.
    Sherman DJ; Liu L; Mamrosh JL; Xie J; Ferbas J; Lomenick B; Ladinsky MS; Verma R; Rulifson IC; Deshaies RJ
    bioRxiv; 2023 Oct; ():. PubMed ID: 37873239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.
    Caon E; Martins M; Hodgetts H; Blanken L; Vilia MG; Levi A; Thanapirom K; Al-Akkad W; Abu-Hanna J; Baselli G; Hall AR; Luong TV; Taanman JW; Vacca M; Valenti L; Romeo S; Mazza G; Pinzani M; Rombouts K
    J Hepatol; 2024 Jun; 80(6):941-956. PubMed ID: 38365182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A PNPLA3-Deficient iPSC-Derived Hepatocyte Screen Identifies Pathways to Potentially Reduce Steatosis in Metabolic Dysfunction-Associated Fatty Liver Disease.
    Doueiry C; Kappler CS; Martinez-Morant C; Duncan SA
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.
    Cherubini A; Ostadreza M; Jamialahmadi O; Pelusi S; Rrapaj E; Casirati E; Passignani G; Norouziesfahani M; Sinopoli E; Baselli G; Meda C; Dongiovanni P; Dondossola D; Youngson N; Tourna A; Chokshi S; Bugianesi E; ; Della Torre S; Prati D; Romeo S; Valenti L
    Nat Med; 2023 Oct; 29(10):2643-2655. PubMed ID: 37749332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
    Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
    World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.
    Banini BA; Kumar DP; Cazanave S; Seneshaw M; Mirshahi F; Santhekadur PK; Wang L; Guan HP; Oseini AM; Alonso C; Bedossa P; Koduru SV; Min HK; Sanyal AJ
    Hepatology; 2021 Apr; 73(4):1290-1306. PubMed ID: 33131062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and Optimization of a Minor Allele-Specific siRNA to Prevent PNPLA3 I148M-Driven Nonalcoholic Fatty Liver Disease.
    Murray JK; Long J; Liu L; Singh S; Pruitt D; Ollmann M; Swearingen E; Hardy M; Homann O; Wu B; Holder JR; Sham K; Herberich B; Lo MC; Dou H; Shkumatov A; Florio M; Rulifson IC
    Nucleic Acid Ther; 2021 Oct; 31(5):324-340. PubMed ID: 34297902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.
    Lindén D; Ahnmark A; Pingitore P; Ciociola E; Ahlstedt I; Andréasson AC; Sasidharan K; Madeyski-Bengtson K; Zurek M; Mancina RM; Lindblom A; Bjursell M; Böttcher G; Ståhlman M; Bohlooly-Y M; Haynes WG; Carlsson B; Graham M; Lee R; Murray S; Valenti L; Bhanot S; Åkerblad P; Romeo S
    Mol Metab; 2019 Apr; 22():49-61. PubMed ID: 30772256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
    Volkert I; Fromme M; Schneider C; Candels L; Lindhauer C; Su H; Thorhauge K; Pons M; Mohamed MR; Schneider KM; Strnad P; Trautwein C
    Hepatology; 2024 Apr; 79(4):898-911. PubMed ID: 37625151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease.
    Basu Ray S
    Adipocyte; 2019 Dec; 8(1):201-208. PubMed ID: 31062641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality.
    Kim HS; Xiao X; Byun J; Jun G; DeSantis SM; Chen H; Thrift AP; El-Serag HB; Kanwal F; Amos CI
    JAMA Netw Open; 2022 Oct; 5(10):e2234221. PubMed ID: 36190732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals.
    Su H; Haque M; Becker S; Edlund K; Duda J; Wang Q; Reißing J; Marschall HU; Candels LS; Mohamed M; Sjöland W; Liao L; Drexler SA; Strowig T; Rahnenführer J; Hengstler JG; Hatting M; Trautwein C
    Liver Int; 2023 Aug; 43(8):1699-1713. PubMed ID: 37073116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PNPLA3 downregulation exacerbates the fibrotic response in human hepatic stellate cells.
    Rady B; Nishio T; Dhar D; Liu X; Erion M; Kisseleva T; Brenner DA; Pocai A
    PLoS One; 2021; 16(12):e0260721. PubMed ID: 34879108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activin A levels in metabolic dysfunction-associated steatotic liver disease associates with fibrosis and the PNPLA3 I148M variant.
    Jönsson C; Bergram M; Kechagias S; Nasr P; Ekstedt M
    Scand J Gastroenterol; 2024 Jun; 59(6):737-741. PubMed ID: 38563432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of
    Liu M; Park S
    Nutrients; 2024 Apr; 16(8):. PubMed ID: 38674929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PNPLA3 mediates hepatocyte triacylglycerol remodeling.
    Ruhanen H; Perttilä J; Hölttä-Vuori M; Zhou Y; Yki-Järvinen H; Ikonen E; Käkelä R; Olkkonen VM
    J Lipid Res; 2014 Apr; 55(4):739-46. PubMed ID: 24511104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.
    Tilson SG; Morell CM; Lenaerts AS; Park SB; Hu Z; Jenkins B; Koulman A; Liang TJ; Vallier L
    Hepatology; 2021 Dec; 74(6):2998-3017. PubMed ID: 34288010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells.
    Pirazzi C; Valenti L; Motta BM; Pingitore P; Hedfalk K; Mancina RM; Burza MA; Indiveri C; Ferro Y; Montalcini T; Maglio C; Dongiovanni P; Fargion S; Rametta R; Pujia A; Andersson L; Ghosal S; Levin M; Wiklund O; Iacovino M; Borén J; Romeo S
    Hum Mol Genet; 2014 Aug; 23(15):4077-85. PubMed ID: 24670599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis.
    He S; McPhaul C; Li JZ; Garuti R; Kinch L; Grishin NV; Cohen JC; Hobbs HH
    J Biol Chem; 2010 Feb; 285(9):6706-15. PubMed ID: 20034933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.